Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 1, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Vectibix Meets Primary Endpoint In Phase III Wild-Type KRAS Colorectal Cancer Trial

 

A phase III study comparing Vectibix (panitumumab) and best supportive care met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer.

This is the first phase III Vectibix study to include an analysis of efficacy of Vectibix by wild-type KRAS (exon 2) and in wild-type RAS tumor mutation status in its primary analysis, according to Amgen, the drug’s sponsor.

The study results, in addition to secondary endpoint data, were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter